CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Core companion animal health	$ 26,386	$ 20,983	$ 74,284	$ 61,312
Other vaccines, pharmaceuticals and products	7,044	7,051	16,257	13,526
Total revenue, net	33,430	28,034	90,541	74,838
Cost of revenue	19,712	16,437	52,699	42,860
Gross profit	13,718	11,597	37,842	31,978
Operating expenses:
Selling and marketing	5,490	5,173	16,495	15,872
Research and development	507	493	1,605	1,304
General and administrative	3,229	3,789	9,724	9,810
Total operating expenses	9,226	9,455	27,824	26,986
Operating income	4,492	2,142	10,018	4,992
Interest and other expense (income), net	14	(69)	(85)	105
Income before income taxes	4,478	2,211	10,103	4,887
Income tax expense:
Current income tax expense	123	106	284	232
Deferred income tax expense	1,012	722	2,287	1,511
Total income tax expense	1,135	828	2,571	1,743
Net income	3,343	1,383	7,532	3,144
Net income (loss) attributable to non-controlling interest	(4)	(32)	477	(66)
Net income attributable to Heska Corporation	$ 3,347	$ 1,415	$ 7,055	$ 3,210
Earnings Per Share [Abstract]
Basic earnings per share attributable to Heska Corporation, in dollars per share	$ 0.49	$ 0.22	$ 1.05	$ 0.51
Diluted earnings per share attributable to Heska Corporation, in dollars per share	$ 0.45	$ 0.20	$ 0.97	$ 0.46
Weighted average outstanding shares used to compute basic earnings per share attributable to Heska Corporation	6,871	6,344	6,727	6,270
Weighted average outstanding shares used to compute diluted earnings per share attributable to Heska Corporation	7,454	7,139	7,299	7,041